OM
MRTX

Opaleye Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Opaleye Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-105,000
Closed -$7.7M – 57
2019
Q1 		$7.7M Buy
+105,000
New +$7.14M 2.13% 19

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Opaleye Management's MRTX Position: Q2 2019 in Review

Opaleye Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 105,000 shares — an estimated $7.7M sold.

Opaleye Management first reported a position in MRTX in Q1 2019 and held it in 1 quarter. The position peaked at $7.7M in Q1 2019. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

  • Opaleye Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Opaleye Management sold 105,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $7.7M.
  • Opaleye Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Opaleye Management's Mirati Therapeutics, Inc. Common Stock position peaked at $7.7M in Q1 2019.
  • 172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.